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 259 
Abstract 260 
Previous studies have suggested that polymorphisms in CASP8 on chromosome 2 are 261 
associated with breast cancer risk. To clarify the role of CASP8 in breast cancer susceptibility 262 
we carried out dense genotyping of this region in the Breast Cancer Association Consortium 263 
(BCAC). Single nucleotide polymorphisms (SNPs) spanning a 1Mb region around CASP8 264 
were genotyped in 46,450 breast cancer cases and 42,600 controls of European origin from 41 265 
studies participating in the BCAC as part of a custom genotyping array experiment (iCOGS). 266 
Missing genotypes and SNPs were imputed and, after quality exclusions, 501 typed and 1,232 267 
imputed SNPs were included in logistic regression models adjusting for study and ancestry 268 
principal components. The SNPs retained in the final model were investigated further in data 269 
from nine genome-wide association studies (GWAS) comprising in total 10,052 case and 270 
12,575 control subjects. The most significant association signal observed in European 271 
subjects was for the imputed intronic SNP rs1830298 in ALS2CR12 (telomeric to CASP8), 272 
with per allele odds ratio and 95% confidence interval [OR (95% CI)] for the minor allele of 273 
1.05 (1.03-1.07), p=1x10
-5
. Three additional independent signals from intronic SNPs were 274 
identified, in CASP8 (rs36043647), ALS2CR11 (rs59278883) and CFLAR (rs7558475). The 275 
association with rs1830298 was replicated in the imputed results from the combined GWAS 276 
(p=3 x10
-6
), yielding a combined OR (95% CI) of 1.06 (1.04-1.08), p=1x10
-9
. Analyses of 277 
gene expression associations in peripheral blood and normal breast tissue indicate that CASP8 278 
might be the target gene, suggesting a mechanism involving apoptosis. 279 
  280 
Introduction 281 
Breast cancer is a complex disease with high, moderate and low penetrance germ-line variants 282 
involved in its aetiology (1). In recent years around 80 low penetrance breast cancer alleles 283 
have been identified, with modest odds ratios, ranging from 1.05-1.4, and together accounting 284 
for around 15% of familial breast cancer risk (2, 3). It is likely that there are many more loci 285 
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with even smaller effect sizes that remain to be identified, accounting for a further 14-15% of 286 
familial risk (2). One of the first low penetrance breast cancer variant associations to be 287 
convincingly replicated by large case-control studies was the single nucleotide polymorphism 288 
(SNP) rs1045485 encoding the mis-sense alteration D302H in the caspase 8 apoptosis-related 289 
cysteine peptidase (CASP8) gene at chromosome region 2q33 (4, 5). This association was 290 
first identified by a candidate gene study and replicated in 2007 by the Breast Cancer 291 
Association Consortium (BCAC), in a study of more than 17,000 cases and 16,000 controls (4, 292 
5). The minor C allele, common in Europeans and rare in Asians, was found to be associated 293 
with a 10% reduction in risk of breast cancer (5). However, further fine-mapping studies have 294 
shown that other variants in the region are associated with an increased risk of breast cancer, 295 
and in the recent large-scale genotyping study carried out by the BCAC as part of the COGS 296 
(Collaborative Oncology Gene- environment Study), rs1045485 showed only weak evidence 297 
of association with breast cancer risk (2, 6, 7). In addition, in 2010 a UK genome-wide 298 
association study (GWAS) of 3,659 cases and 4,897 controls found suggestive evidence of 299 
association [OR (95% CI) 1.14 (1.06-1.22); p=1.5x10
-4
] with an independent variant in the 300 
region; rs10931936, a CASP8 intronic SNP, that is only weakly correlated with rs1045485 301 
(r
2
=0.083) (8).  302 
 303 
In order to clarify the breast cancer risk association(s) at this locus, we have analysed 501 304 
SNPs across a 1Mb region surrounding CASP8, for 89,050 women, as part of a custom-305 
designed Illumina genotyping chip – the iCOGS array. We present here the results of this 306 
fine-mapping analysis, together with a meta-analysis across iCOGS and the combined data 307 
from nine breast cancer GWAS, followed by an examination of associations between the key 308 
SNPs and RNA expression levels. 309 
 310 
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Results 311 
Breast cancer risk associations in the CASP8 region on chromosome 2 312 
A summary of the breast cancer risk associations of 1,733 typed and imputed SNPs across a 313 
1Mb region surrounding CASP8, based on the iCOGS European data, is shown in Figure 1. 314 
The most significant associations were for SNPs in the CASP8 and ALS2CR12 (amyotrophic 315 
lateral sclerosis 2 (juvenile) chromosome region, candidate 12) genes (Figure 1 and Table S2). 316 
The strongest signals came from imputed SNP rs1830298 in ALS2CR12, with MAF (minor 317 
allele frequency) of 0.29 and an estimated OR (95% CI) per copy of the minor allele of 1.05 318 
(1.03-1.07), p=1.1x10
-5
, and the genotyped SNP rs10197246, (MAF=0.28), with odds ratio 319 
(95% CI) 1.05 (1.02-1.07), p=2.5x10
-5
. These two SNPs are highly correlated and likely 320 
reflect the same signal (r
2
=0.9). 321 
 322 
Two previously reported susceptibility SNPs, CASP8 D302H (rs1045485) and rs10931936, 323 
were weakly replicated in iCOGS European data (Table S2), with minor allele OR in the same 324 
direction; however, the iCOGS OR estimates were much weaker than those from the original 325 
reports (5, 8). The minor C allele of rs1045485 (MAF=0.11) yielded an OR (95% CI) of 0.97 326 
(0.94-1.0), p=0.03, in contrast to 0.88 (0.84-0.92) reported in Cox et al (5). Similarly, the 327 
rs10931936 minor allele (MAF=0.28) was associated with a 4% increased breast cancer risk 328 
[OR (95% CI)=1.04 (1.02-1.06), p=1.9x10
-4
], compared to the 12% increase presented in 329 
Turnbull et al. (8). The latter SNP is strongly correlated with the iCOGS best hit rs1830298 330 
(r
2
=0.96), but there is very little correlation between rs1045485 and rs1830298 (r
2
=0.055). 331 
 332 
Identification of possible independent signals in iCOGS European data 333 
The SNPs in the main association peak have similar ORs for breast cancer, are strongly 334 
correlated with one another (r
2
>0.66) and confined to an 82 Kb region spanning the CASP8 335 
and ALS2CR12 genes, and are therefore likely to reflect a single association signal, but this 336 
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does not preclude the possibility of other signals in the region. To test this hypothesis, we 337 
carried out a regression analysis testing the association of individual SNPs adjusted for the 338 
top hit rs1830298, in the iCOGS European data set (Table S3). Interestingly, whilst this 339 
resulted in the loss of the signal from the main peak in CASP8/ALS2CR12, residual 340 
associations remained (for example 43 SNPs with p≤1x10-3), suggesting that there may be 341 
further signals present in the region, albeit weaker (Table S3 and Figure S1). To investigate 342 
this further, we carried out penalised logistic regression analysis of all 1,733 SNPs to identify 343 
the best subset of SNPs that explain the association, using HyperLasso (9). This identified 59 344 
models containing combinations of 27 SNPs (Table S2), but many of these models were 345 
equivalent after taking into account linkage disequilibrium between SNPs. To obtain the most 346 
parsimonious model, we carried out stepwise forward logistic regression on the 27 SNPs, 347 
which resulted in a model containing four SNPs; rs1830298 (ALS2CR12; pconditional=9.3x10
-3
, 348 
MAF=0.29), rs36043647 (CASP8; pconditional=1.9x10
-4
, MAF=0.06), rs59278883 (ALS2CR11; 349 
pconditional=6.1x10
-4
, MAF=0.07) and rs7558475 (CFLAR; CASP8 and FADD-like apoptosis 350 
regulator; pconditional=9.2x10
-4
, MAF=0.07). We refer to these four SNPs, marking four 351 
independent sets of correlated highly associated variants (iCHAVs), as index SNPs. 352 
 353 
Meta-analysis of iCOGS and combined nine GWAS data 354 
We first examined the results for the four index SNPs, together with the previous hits 355 
rs1045485 and rs10931936, in the combined nine GWAS meta-analysis, and then carried out 356 
a further meta-analysis combining the iCOGS European data with the combined nine GWAS 357 
for these SNPs (total sample size 56,502 cases and 55,175 controls; Tables S4 and S5). We 358 
found that the top index SNP, rs1830298, replicated in the combined GWAS data alone 359 
(p=2.7x10
-6
), and reached genome-wide significance (p=1.1x10
-9
) in the meta-analysis 360 
containing both the iCOGS and combined GWAS data (Table S5 and Figure 2). The 361 
genotyped proxy rs10197246 also reached genome-wide significance (p=1.7x10
-8
). When we 362 
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examined the other three index SNPs in the combined GWAS data, we found a replicated 363 
association (p=1.8x10
-3
) for rs59278883, a null result for rs36043647 (p=0.58) and borderline 364 
evidence for rs7558475 (p=0.05) (Table S5 and Figure 2). However these three index SNPs 365 
all showed some evidence of association in the meta analysis of iCOGS and combined 366 
GWAS (Table S5 and Figure 2), providing some support for the existence of four signals in 367 
the region. Consistent with its strong correlation with rs1830298, a similar but slightly weaker 368 
signal was found for rs10931936 in the combined analysis (p=1.0x10
-7
). Weak evidence for 369 
association was observed for CASP8 D302H rs1045485 (p=1.1x10
-3
).  370 
 371 
Analysis of index SNPs in different ethnic groups 372 
We next explored these four associations in the available Asian and African-American 373 
populations genotyped as part of COGS (Figure 3 and Table S6). Figure 3 shows the study-374 
specific OR for rs1830298 by the three ethnic groups. The rs1830298 OR were homogeneous 375 
among European studies (phet=0.54, I
2
=0) and African-American studies (phet=0.40, I
2
=0), but 376 
were more heterogeneous amongst the nine Asian studies (phet=0.025, I
2
=54), although the 377 
combined effect size in Asians was similar to that seen in Europeans [OR (95% CI)=1.04 378 
(0.95-1.13); p=0.44], and slightly stronger in African-Americans [OR (95% CI)=1.12 (0.96-379 
1.30); p=0.16]. Although estimates in both Asian and African-American populations were not 380 
statistically significant, the OR were consistent with the European data, and the pooled OR 381 
(95% CI) was 1.05 (1.03-1.07); p=4.1x10
-6
 for all populations combined. The MAF of CASP8 382 
rs36043647 was much lower in Asians, in whom the association was in the opposite direction 383 
to that in Europeans and African-Americans, with an OR (95% CI) of 1.69 (1.13-2.51), 384 
p=0.009, for the minor allele (Table S6). We did not observe any association of rs59278883 385 
and rs7558475 in Asian and African-American populations (Table S6). 386 
 387 
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Subtype and survival analysis in iCOGS   388 
To investigate whether these SNP associations vary with clinical subtypes of breast cancer, 389 
we explored potential subtype-specific associations by comparing different subtypes to all 390 
controls in the iCOGS European data. The OR estimates by tumour estrogen receptor (ER) 391 
status, triple negative status and invasiveness of breast cancer were all similar and close to the 392 
OR of 1.05 seen in overall breast cancer for rs1830298 (Figure 4). Similarly no significant 393 
differences in OR were seen when cases were stratified by family history, tumour grade, 394 
tumour stage, tumour size and lymph node status (Figure S2). A broadly similar picture was 395 
seen for the other index SNPs (Figures S2 and S3). 396 
 397 
SNP effects were also evaluated for overall survival and breast-cancer-specific survival. 398 
There were 4,191 deaths among 39,140 breast cancer patients with known vital status in the 399 
European dataset. Of these deaths, 1,979 died from breast cancer. We did not observe any 400 
associations between the index SNPs or previous hit SNPs with either overall or breast 401 
cancer-specific survival, and all hazard ratios (HR) were close to unity (data not shown). 402 
 403 
In silico functional and eQTL annotations 404 
We examined available in silico functional and expression quantitative trait loci (eQTL) data 405 
for the four iCHAVs. Of interest in iCHAV1, rs3769823 is a missense alteration encoding 406 
K14R in the 4
th
 exon of CASP8, which encodes the N-terminus of protein isoform 9. In 407 
addition, this SNP and rs3769821 are both located in a region of deoxyribonuclease I (DNase 408 
I) hypersensitivity and histone H3K27 acetylation in breast cell lines (Figure 5). The minor 409 
alleles of both of these SNPs, together with four others in iCHAV1 for which data were 410 
available, were associated with a reduction in CASP8 mRNA levels in peripheral blood 411 
samples in the eQTL meta-analysis of Westra et al (p≤9.4x10-5; Table S7, Figure 5) (10). The 412 
cancer genome atlas (TCGA) dataset only had data available for two SNPs from iCHAV1, 413 
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and both were associated with a reduction in CASP8 mRNA in normal breast tissue (p≤1x10-3; 414 
Table S7, Figure 5). No strong eQTL associations were seen for other genes in the region in 415 
either the Westra et al. or the TCGA data. Taken together, these data suggest that one or more 416 
variants in iCHAV1 may affect levels of CASP8 gene expression. As shown in Figure 5, 417 
iCHAVs 3 and 4 overlap enhancer sites identified in Hnisz et al; a CASP8 enhancer in MCF7 418 
cells and a CFLAR enhancer in human mammary epithelial cells (HMEC), respectively (11). 419 
However, there was limited eQTL data available for these iCHAVs, with no evidence of any 420 
significant eQTLs (Table S7). 421 
 422 
Discussion 423 
In our analysis of the genomic region surrounding CASP8 for association with breast cancer, 424 
the strongest signal came from an imputed SNP, rs1830298, in the ASL2CR12 gene 425 
(iCHAV1). A strongly correlated genotyped SNP, (rs10197246; r
2
=0.9, 23.5 Kb telomeric in 426 
the same gene), yielded a similar association signal (p=1.1x10
-5
 and 2.5x10
-5 
respectively). In 427 
each case, the rare allele (MAF=0.28) was associated with an increase in the risk of breast 428 
cancer of 5% [OR(95% CI) 1.05 (1.03, 1.07) and 1.05 (1.02, 1.07) respectively]. The odds 429 
ratios for both SNPs are consistent in Europeans, Asians and African-Americans, (although 430 
not statistically significant in the smaller non-European cohorts), and were replicated in the 431 
combined GWAS data, achieving a genome-wide level of significance when the iCOGS and 432 
GWAS data were combined (p=1.1x10
-9
 and p=1.7x10
-8
 respectively). This association is 433 
consistent between ER positive and negative disease, and between invasive and in situ cancers 434 
(Figure 4). The previously published result for rs10931936 in the UK GWAS is consistent 435 
with its correlation with rs1830298 (8).  436 
 437 
Several of the SNPs in iCHAV1were associated with CASP8 eQTLs. The minor alleles of 438 
SNPs in this group, associated with increased risk of breast cancer, are associated with 439 
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reduced CASP8 mRNA levels in both peripheral blood lymphocytes and normal breast tissue 440 
(Table S7, Figure 5). These data suggest that CASP8 may be the target gene of iCHAV1, and 441 
are consistent with a hypothesis in which the effect of the risk alleles is via reduced levels of 442 
apoptosis, thus promoting tumour initiation. However, further functional studies are required 443 
to demonstrate a direct interaction between iCHAV1 and the CASP8 promoter and to 444 
investigate the allele-specific functional effects of these SNPs in different tissue types.  445 
 446 
Our results also suggest three other independent signals in the region; the most significant 447 
SNPs for these three signals are in CASP8 (iCHAV2), ALS2CR11 (iCHAV3), and in the anti-448 
apoptotic gene CFLAR (iCHAV4); see Figure 2 and Table S5. The signals for iCHAVs 3 and 449 
4 were replicated in the combined GWAS, but since they did not achieve genome-wide levels 450 
of significance even in the very large data sets analysed here, they are harder to interpret. 451 
However, it is interesting that both these iCHAVs overlap enhancer regions (Figure 5).  452 
 453 
As previously noted, we find only very weak support for an association of rs1045485/D302H 454 
in the iCOGS data (p=0.03; (2)), although the odds ratio in the combined GWAS data was 455 
more consistent with the original report [OR (95% CI)=0.90(0.85, 0.96), p=0.0007] (5). At 456 
present the reasons for the discrepancy with the original report are not clear. D302H is only 457 
weakly correlated with any of the four index SNPs identified here (max r
2
=0.06 with 458 
rs1830298). However, it is correlated with rs28845859 (r
2
=0.67); the latter SNP is associated 459 
with reduced breast cancer risk in the iCOGS data (OR 0.95, p=1.9x10
-4
; Table S2) and 460 
combined GWAS  (p=4.0x10
-5
). We found no significant differences between sub-types, 461 
although the associated effect for D302H was stronger (and borderline significant) for triple 462 
negative disease, despite the smaller sample size (Figure S3). Further investigation with a 463 
larger sample of triple negative cases may help clarify this point. 464 
 465 
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The association for the top CASP8 index SNP, rs1830298, represents one of the smaller effect 466 
sizes identified to date for breast cancer. However it is worth noting that the CASP8 region 467 
has recently been reported to be associated with other cancers at genome-wide levels of 468 
significance, including melanoma and chronic lymphocytic leukaemia (CLL) (12, 13). The 469 
alleles associated with increased risk in melanoma are correlated with rs1830298, but the 470 
signal in CLL appears to be due to uncorrelated SNPs in the region. This difference may 471 
reflect the different cell type of origin and it will be interesting to determine the relative 472 
importance and function of alleles of the CASP8 gene family in immune cell lineages, 473 
compared to that in epithelial cancers. 474 
 475 
Materials and Methods 476 
Study samples  477 
The iCOGS and nine breast cancer GWAS data sets have been described in detail previously 478 
(2). Briefly, the COGS includes a total of 103,991 women from 50 studies participating in the 479 
BCAC whose DNA samples were genotyped with the iCOGS array. These were 89,050 480 
Europeans (46,450 cases; 42,600 controls), 12,893 Asians (6,269 cases; 6,624 controls), and 481 
2,048 African-Americans (1,116 cases and 932 controls). The numbers of subjects by study 482 
are detailed in Table S1. Approximately 93% of cases had invasive breast cancer (Table S1). 483 
The combined nine breast cancer GWAS data set comprised 10,052 cases and 12,575 controls 484 
of European ancestry from USA, UK, Australia, Germany, Finland, Sweden and the 485 
Netherlands (2). 486 
 487 
Ethics statement 488 
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Each study was approved by the relevant local/institutional Research Ethics Committee, and 489 
all subjects gave written informed consent to take part. 490 
 491 
SNP selection for fine-scale mapping on the iCOGS array The region for analysis on 492 
chromosome 2 was defined such that it contained all SNPs correlated (r
2≥0.1) with the SNPs 493 
previously reported to be associated with breast cancer, namely, CASP8 D302H (rs1045485) 494 
and rs10931936 (5, 8). This identified a 1Mb region from 201,566,128 to 202,566,128 (hg19). 495 
In March 2010 when the iCOGS array was designed, 2,191 SNPs had been catalogued in this 496 
region by the 1000 genomes and HapMap3 projects. Of these, 1,723 SNPs had a MAF ≥2%, 497 
and of these 1,723, there were 988 SNPs with Illumina assay design scores of ≥ 0.8. We 498 
selected a total of 280 SNPs correlated at r
2≥0.1 with rs1045485 or rs10931936, plus 288 499 
tagSNPs which tagged the remaining 708 SNPs at r
2≥0.9. Another 45 SNPs in the region, 500 
nominated by other consortia members, were included as part of the genotyping array that 501 
comprised 211,155 SNPs in total (2). 502 
 503 
Genotyping & quality control  504 
Genotyping, allele calling, quality control and principal components analysis for COGS are 505 
described in detail in Michailidou et al. (2). Genotyping was carried out at four centres using 506 
the Illumina Infinium iCOGS array, including 2% duplicates from each participating study. 507 
Final genotype calls were made using Illumina's proprietary GenCall algorithm. SNPs were 508 
excluded from analysis if the overall call rate was <95%, duplicate concordance rate was 509 
<98%, or if deviation from Hardy-Weinberg equilibrium in controls was significant at 510 
p<1x10
-7
 (2). Subjects were excluded from analysis for the following reasons: genotypically 511 
non female; overall call rate < 95%; low or high heterozygosity (P<1×10
−6
); discordant 512 
replicates or cryptic duplicates. Genotype data and ancestry principal components (seven 513 
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principal components for the European and two each for the Asian and African-American 514 
populations) were thus available for 103,991 individuals. 515 
 516 
Statistical analysis  517 
The iCOGS CASP8 region genotype data were split into four groups for efficiency of 518 
imputation of missing genotypes and untyped SNPs. These comprised 36,793 European 519 
ancestry subjects from North American and UK studies in group 1, with 26,129 and 26,128 of 520 
the remaining European subjects in groups 2 and 3 respectively, and 14,941 Asians and 521 
African-Americans in group 4. Imputations were carried out separately by group based on the 522 
1000 genomes phase I reference panel with singleton variants excluded, using IMPUTE2 523 
version 2.3 (14, 15). SNPs were included in the subsequent analyses if the mean information 524 
score of the European groups was ≥ 0.9, and untyped imputed SNPs were only included if 525 
their MAF was ≥3%; these criteria resulted in inclusion of 501 typed and 1,232 imputed SNPs 526 
in the final analysis. The imputation accuracy for rs1830298 was verified in whole genome 527 
sequence data from 197 individuals; the correlation between the observed and imputed 528 
genotypes was 0.974. The imputation step increases the number of common SNPs captured at 529 
r
2
>0.9 from 76% (1198/1583) to 84% (1333/1583). 530 
 531 
The main analyses were based on the data for individuals of European ancestry. For each SNP, 532 
allelic dosage of the minor allele was estimated, and included in a logistic regression model, 533 
to estimate OR and corresponding 95% CI. Covariates for each study plus the seven ancestry 534 
principal components were included in the model (2). These analyses were implemented in R. 535 
P-values from the Wald test are reported in the text (uncorrected for multiple testing). FDR 536 
values in Table S2 were calculated according to the Benjamini & Hochberg method, as 537 
implemented in the R p.adjust function (16). Penalised logistic regression models (based on 538 
the normal exponential gamma probability density) were implemented in HyperLasso (9), 539 
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including all 501 typed and 1,232 imputed SNPs, to identify the best subsets of SNPs to 540 
account for the observed association data. Based on the sample size and a type I error of 0.001, 541 
a lambda of 0.05 and penalty of 491 were specified in HyperLasso, according to equation 7 in 542 
Hoggart et al. (9). Candidate SNPs were then compiled from the resulting HyperLasso models 543 
and included in a stepwise forward logistic regression procedure with penalty k=10 in the step 544 
function in R to identify the most parsimonious model, as described previously (17). The 545 
SNPs retained in the final model are referred to as index SNPs. 546 
 547 
Index SNPs were further examined by means of meta-analysis of iCOGS European, Asian 548 
and African-American data, and also with individual SNP results from the combined nine 549 
breast cancer GWAS (2). Due to an overlap of 1,955 samples that exist in both the iCOGS 550 
and the combined GWAS data, we removed these samples from the iCOGS data before 551 
carrying out the meta-analysis. The meta-analysis was carried out using the MetaFor package 552 
in R, with inverse-variance weights and the DerSimonian-Laird estimator for the random 553 
effects model (18). We used the threshold of p=5x10
-8
 to define genome-wide significance (2). 554 
 555 
The index SNPs were also examined for associations with breast cancer specific and overall 556 
survival in Cox’s proportional hazard models, including age at diagnosis, study and seven 557 
principal components as covariates, and accounting for the left-censoring time between study 558 
entry and diagnosis. Further adjustment was carried out for stage, grade, tumour size, and 559 
lymph node involvement for SNPs with nominally significant associations with survival 560 
(p<0.05). These analyses were implemented in R.  561 
 562 
In silico functional and eQTL annotations  563 
We defined independent sets of correlated highly associated variants (iCHAVs) with 564 
likelihood (determined from the individual-SNP logistic regression analysis) relative to an 565 
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index SNP of greater than 1/100 and degree of correlation with the index SNP of greater than 566 
0.65. The ENCODE integrated regulation data for each SNP were retrieved from the UCSC 567 
Genome Browser by use of ANNOVAR (19). Predicted enhancers and target genes were 568 
retrieved from Hnisz et al. (11). Expression QTL data were obtained by interrogation of the 569 
GTEx Portal, the online results of the peripheral blood eQTL meta-analysis based on 5,311 570 
samples from 7 studies by Westra and colleagues (10), and from breast cancer cases in the 571 
TCGA Project. For the latter, RNAseq data in the form of fragments per Kb of transcript per 572 
million mapped reads (FPKM) were available for uninvolved breast tissue from 97 TCGA 573 
breast cancer cases. Peripheral blood DNA SNP genotypes for these individuals were 574 
extracted from the TCGA Level 2 Affymetrix 6.0 array birdseed files. Mean FPKM were 575 
compared between individuals homozygous for the common allele and those carrying one or 576 
two copies of the rare allele by use of an unpaired, unequal variance T-test in Stata.  577 
578 
 24 
 579 
Acknowledgements 580 
Part of this work was supported by the European Community´s Seventh Framework 581 
Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) 582 
(COGS). Funding for the iCOGS infrastructure came from: the European Community's 583 
Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-584 
223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, 585 
C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of 586 
Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 587 
and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-588 
1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial 589 
Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research 590 
Foundation, and the Ovarian Cancer Research Fund. The ABCFS, NC-BCFR and OFBCR 591 
work was supported by the United States National Cancer Institute, National Institutes of 592 
Health (NIH) under RFA-CA-06-503 and through cooperative agreements with members of 593 
the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer 594 
Care Ontario (U01 CA69467), Northern California Cancer Center (U01 CA69417), 595 
University of Melbourne (U01 CA69638). Samples from the NC-BCFR were processed and 596 
distributed by the Coriell Institute for Medical Research. The content of this manuscript does 597 
not necessarily reflect the views or policies of the National Cancer Institute or any of the 598 
collaborating centers in the BCFR, nor does mention of trade names, commercial products, or 599 
organizations imply endorsement by the US Government or the BCFR. The ABCFS was also 600 
supported by the National Health and Medical Research Council of Australia, the New South 601 
Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the 602 
Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical 603 
Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research 604 
Consortium Group Leader.  M.C.S. is a NHMRC Senior Research Fellow and a Victorian 605 
 25 
Breast Cancer Research Consortium Group Leader. The ABCS was supported by the Dutch 606 
Cancer Society [grants NKI 2007-3839; 2009 4363]; BBMRI-NL, which is a Research 607 
Infrastructure financed by the Dutch government (NWO 184.021.007); and the Dutch 608 
National Genomics Initiative. The ACP study is funded by the Breast Cancer Research Trust, 609 
UK. The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of 610 
Erlangen. The BBCS is funded by Cancer Research UK and Breakthrough Breast Cancer and 611 
acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National 612 
Cancer Research Network (NCRN). The BBCS GWAS received funding from The Institut 613 
National de Cancer. ES is supported by NIHR  Comprehensive Biomedical Research Centre, 614 
Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, 615 
United Kingdom. IT is supported by the Oxford Biomedical Research Centre. The BSUCH 616 
study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the 617 
German Cancer Research Center (DKFZ). The CECILE study was funded by Fondation de 618 
France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Ligue contre le 619 
Cancer Grand Ouest, Agence Nationale de Sécurité Sanitaire (ANSES), Agence Nationale de 620 
la Recherche (ANR). The was supported by the Chief Physician Johan Boserup and Lise 621 
Boserup Fund, the Danish Medical Research Council and Herlev Hospital. The CNIO-BCS 622 
was supported by the Genome Spain Foundation, the Red Temática de Investigación 623 
Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the 624 
Fondo de Investigación Sanitario (PI11/00923 and PI081120). The Human Genotyping-625 
CEGEN Unit (CNIO) is supported by the Instituto de Salud Carlos III. The CTS was 626 
supported by the California Breast Cancer Act of 1993; National Institutes of Health (grants 627 
R01 CA77398 and the Lon V Smith Foundation [LVS39420].); the California Breast Cancer 628 
Research Fund (contract 97-10500). Collection of cancer incidence data used in this study 629 
was supported by the California Department of Public Health as part of the statewide cancer 630 
reporting program mandated by California Health and Safety Code Section 103885. The 631 
 26 
ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, 632 
Research and Arts. Additional cases were recruited in the context of the VERDI study, which 633 
was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The GC-634 
HBOC was supported by Deutsche Krebshilfe (107 352). The GENICA was funded by the 635 
Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 636 
01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, 637 
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and 638 
Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr 639 
University Bochum  (IPA), Bochum, Germany, as well as the Department of Internal 640 
Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. 641 
The HEBCS was financially supported by the Helsinki University Central Hospital Research 642 
Fund, Academy of Finland (266528), the Finnish Cancer Society, The Nordic Cancer Union 643 
and the Sigrid Juselius Foundation. The GWS population allele and genotype frequencies 644 
were obtained from the data source funded by the Nordic Center of Excellence in Disease 645 
Genetics based on samples regionally selected from Finland, Sweden and Denmark. The 646 
HERPACC was supported by a Grant-in-Aid for Scientific Research on Priority Areas from 647 
the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-648 
Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry 649 
Health, Labour and Welfare of Japan, by Health and Labour Sciences Research Grants for 650 
Research on Applying Health Technology from Ministry Health, Labour and Welfare of 651 
Japan and by National Cancer Center Research and Development Fund. The HMBCS was 652 
supported by a grant from the Friends of Hannover Medical School and by the Rudolf 653 
Bartling Foundation. Financial support for KARBAC was provided through the regional 654 
agreement on medical training and clinical research (ALF) between Stockholm County 655 
Council and Karolinska Institutet, The Swedish Cancer Society and the Gustav V Jubilee 656 
foundation. The KBCP was financially supported by the special Government Funding (EVO) 657 
 27 
of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer 658 
Organizations, the Academy of Finland and by the strategic funding of the University of 659 
Eastern Finland. kConFab is supported by grants from the National Breast Cancer Foundation, 660 
the NHMRC, the Queensland Cancer Fund, the Cancer Councils of New South Wales, 661 
Victoria, Tasmania and South Australia and the Cancer Foundation of Western Australia. The 662 
kConFab Clinical Follow Up Study was funded by the NHMRC [145684, 288704, 454508]. 663 
Financial support for the AOCS was provided by the United States Army Medical Research 664 
and Materiel Command [DAMD17-01-1-0729], the Cancer Council of Tasmania and Cancer 665 
Foundation of Western Australia and the NHMRC [199600]. G.C.T. and P.W. are supported 666 
by the NHMRC. LAABC is supported by grants (1RB-0287, 3PB-0102, 5PB-0018, 10PB-667 
0098) from the California Breast Cancer Research Program.  Incident breast cancer cases 668 
were collected by the USC Cancer Surveillance Program (CSP), which is supported under 669 
subcontract by the California Department of Health. The CSP is also part of the National 670 
Cancer Institute's Division of Cancer Prevention and Control Surveillance, Epidemiology, and 671 
End Results Program, under contract number N01CN25403. LMBC is supported by the 672 
'Stichting tegen Kanker' (232-2008 and 196-2010). Diether Lambrechts is supported by the 673 
FWO and the KULPFV/10/016-SymBioSysII. The MARIE study was supported by the 674 
Deutsche Krebshilfe e.V. [70-2892-BR I], the Hamburg Cancer Society, the German Cancer 675 
Research Center and the Federal Ministry of Education and Research (BMBF) Germany 676 
[01KH0402, 01KH0408, 01KH0409]. MBCSG is supported by grants from the Italian 677 
Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated 678 
the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale 679 
Tumori, according to Italian laws (INT-Institutional strategic projects “5x1000”). The 680 
MCBCS was supported by the NIH grant CA128978, an NIH Specialized Program of 681 
Research Excellence (SPORE) in Breast Cancer [CA116201], the Breast Cancer Research 682 
Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation 683 
 28 
and the Ting Tsung and Wei Fong Chao Foundation. MCCS cohort recruitment was funded 684 
by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian 685 
NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer 686 
Council Victoria. The MEC was support by NIH grants CA63464, CA54281, CA098758 and 687 
CA132839. The work of MTLGEBCS was supported by the Quebec Breast Cancer 688 
Foundation, the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks 689 
of Breast Cancer” program – grant # CRN-87521 and the Ministry of Economic 690 
Development, Innovation and Export Trade – grant # PSR-SIIRI-701. MYBRCA is funded by 691 
research grants from the Malaysian Ministry of Science, Technology and Innovation 692 
(MOSTI), Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer 693 
Research Initiatives Foundation (CARIF). Additional controls were recruited by the 694 
Singapore Eye Research Institute, which was supported by a grant from the Biomedical 695 
Research Council (BMRC08/1/35/19/550), Singapore and the National medical Research 696 
Council, Singapore (NMRC/CG/SERI/2010). The NBCS was supported by grants from the 697 
Norwegian Research council, 155218/V40, 175240/S10 to ALBD, FUGE-NFR 181600/V11 698 
to VNK and a Swizz Bridge Award to ALBD. The NBCS was supported by grants from the 699 
Norwegian Research council, 155218/V40, 175240/S10 to ALBD, FUGE-NFR 181600/V11 700 
to VNK and a Swizz Bridge Award to ALBD. The NBHS was supported by NIH grant 701 
R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen 702 
Shared Resource, which is supported by P30 CA68485. The OBCS was supported by research 703 
grants from the Finnish Cancer Foundation, the Academy of Finland Centre of Excellence 704 
grant  251314, the Sigrid Juselius Foundation, the University of Oulu, and the Oulu 705 
University Hospital special Govermental EVO Research Funds. The OFBCR work was 706 
supported by grant UM1 CA164920 from the National Cancer Institute. The content of this 707 
manuscript does not necessarily reflect the views or policies of the National Cancer Institute 708 
or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does 709 
 29 
mention of trade names, commercial products, or organizations imply endorsement by the US 710 
Government or the BCFR. The ORIGO study was supported by the Dutch Cancer Society 711 
(RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure 712 
(BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National 713 
Cancer Institute, Department of Health and Human Services, USA. The pKARMA study was 714 
supported by Märit and Hans Rausings Initiative Against Breast Cancer. The RBCS was 715 
funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC 716 
study was supported by funding from the Agency for Science, Technology and Research of 717 
Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen 718 
Breast Cancer Foundation. The SBCGS was supported primarily by NIH grants R01CA64277, 719 
R01CA148667, and R37CA70867. Biological sample preparation was conducted the Survey 720 
and Biospecimen Shared Resource, which is supported by P30 CA68485. The SBCS was 721 
supported by Yorkshire Cancer Research awards S295, S299, S305PA, and by the Sheffield 722 
Experimental Cancer Medicine Centre Network. NJC was supported by NCI grant R01 723 
CA163353 and The Avon Foundation (02-2009-080). The SCCS is supported by a grant from 724 
the National Institutes of Health (R01 CA092447).  Data on SCCS cancer cases used in this 725 
publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer 726 
Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; 727 
Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina 728 
Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor 729 
Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia 730 
Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer 731 
Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas Central Cancer Registry 732 
is fully funded by a grant from National Program of Cancer Registries, Centers for Disease 733 
Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected 734 
by the Mississippi Cancer Registry which participates in the National Program of Cancer 735 
 30 
Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of 736 
this publication are solely the responsibility of the authors and do not necessarily represent 737 
the official views of the CDC or the Mississippi Cancer Registry. SEARCH is funded by 738 
programme grants from Cancer Research UK [C490/A10124, C490/A16561] and supported 739 
by the UK National Institute for Health Research Biomedical Research Centre at the 740 
University of Cambridge. The SEBCS was supported by the Korea Health 21 R&D Project 741 
[AO30001], Ministry of Health and Welfare, Republic of Korea. SGBCC is funded by the 742 
National Medical Research Council start-up Grant and Centre Grant (NMRC/CG/NCIS 743 
/2010). Additional controls were recruited by the Singapore Consortium of Cohort Studies-744 
Multi-ethnic cohort (SCCS-MEC), which was funded by the Biomedical Research Council, 745 
grant number: 05/1/21/19/425. SKKDKFZS is supported by the DKFZ. The SZBCS was 746 
supported by Grant PBZ_KBN_122/P05/2004. The TBCS was funded by The National 747 
Cancer Institute Thailand. The TNBCC was supported by: MCBCS (National Institutes of 748 
Health Grants CA122340 and a Specialized Program of Research Excellence (SPORE) in 749 
Breast Cancer (CA116201), a generous gift from the David F. and Margaret T. Grohne 750 
Family Foundation and the Ting Tsung and Wei Fong Chao Foundation. This research has 751 
been partly financed by the European Union (European Social Fund – ESF) and Greek 752 
national funds through the Operational Program "Education and Lifelong Learning" of the 753 
National Strategic Reference Framework (NSRF) - Research Funding Program of the General 754 
Secretariat for Research & Technology: ARISTEIA. Investing in knowledge society through 755 
the European Social Fund; and the Stefanie Spielman Breast Fund and the Ohio State 756 
University Comprehensive Cancer Center. The TWBCS is supported by the Taiwan Biobank 757 
project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan. The UKBGS is 758 
funded by Breakthrough Breast Cancer and the Institute of Cancer Research (ICR). ICR 759 
acknowledges NHS funding to the NIHR Biomedical Research Centre. The Nurses’ Health 760 
Studies (CGEMS) are supported by NIH grants CA 65725, CA87969, CA49449, CA67262, 761 
 31 
CA50385 and 5UO1CA098233. The UK2 GWAS was funded by Wellcome Trust and Cancer 762 
Research UK. It included samples collected through the FBCS study, which is funded by 763 
Cancer Research UK [C8620/A8372]. It included control data obtained through the WTCCC 764 
which was funded by the Wellcome Trust. The DFBBCS GWAS was funded by The 765 
Netherlands Organisation for Scientific Research (NWO) as part of a ZonMw/VIDI grant 766 
number 91756341. Control GWA genotype data from the Rotterdam Study were funded by 767 
NWO Groot Investments (project nr. 175.010.2005.011). 768 
 769 
We thank all the individuals who took part in these studies and all the researchers, clinicians, 770 
technicians and administrative staff who have enabled this work to be carried out. This study 771 
would not have been possible without the contributions of the following: Andrew Berchuck 772 
(OCAC), Rosalind A. Eeles, Ali Amin Al Olama, Zsofia  Kote-Jarai, Sara Benlloch 773 
(PRACTICAL), Antonis Antoniou, Lesley McGuffog, Ken Offit (CIMBA), Andrew Lee, and 774 
Ed Dicks, and the staff of the Centre for Genetic Epidemiology Laboratory, the staff of the 775 
CNIO genotyping unit, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill 776 
University and Génome Québec Innovation Centre, the staff of the Copenhagen DNA 777 
laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey 778 
Meyer and the staff of Mayo Clinic Genotyping Core Facility. We also thank Maggie 779 
Angelakos, Judi Maskiell, Gillian Dite (ABCFS), and extend our thanks to the many women 780 
and their families that generously participated in the Australian Breast Cancer Family Study 781 
and consented to us accessing their pathology material.  JLH is a National Health and Medical 782 
Research Council Australia Fellow.  MCS is a National Health and Medical Research Council 783 
Senior Research Fellow. JLH and MCS are both group leaders of the Victoria Breast Cancer 784 
Research Consortium. We thank Sten Cornelissen, Richard van Hien, Linde Braaf, Frans 785 
Hogervorst, Senno Verhoef, Ellen van der Schoot, Femke Atsma (ABCS). The ACP study 786 
wishes to thank the participants in the Thai Breast Cancer study.  Special Thanks also go to 787 
 32 
the Thai Ministry of Public Health (MOPH), doctors and nurses who helped with the data 788 
collection process.   Finally, the study would like to thank Dr Prat Boonyawongviroj, the 789 
former Permanent Secretary of MOPH and Dr Pornthep Siriwanarungsan, the Department 790 
Director-General of Disease Control who have supported the study throughout. We thank 791 
Eileen Williams, Elaine Ryder-Mills, Kara Sargus (BBCS), Niall McInerney, Gabrielle 792 
Colleran, Andrew Rowan, Angela Jones (BIGGS), Peter Bugert, and Medical Faculty 793 
Mannheim (BSUCH). We thank the staff and participants of the Copenhagen General 794 
Population Study, and for excellent technical assistance: Dorthe Uldall Andersen, Maria Birna 795 
Arnadottir, Anne Bank, and Dorthe Kjeldgård Hansen. The Danish Breast Cancer Group 796 
(DBCG) is acknowledged for the tumor information. We thank Guillermo Pita, Charo Alonso, 797 
Daniel Herrero, Nuria Álvarez, Pilar Zamora, Primitiva Menendez, the Human Genotyping-798 
CEGEN Unit (CNIO), Hartwig Ziegler, Sonja Wolf, and Volker Hermann (ESTHER). We 799 
thank Heide Hellebrand, Stefanie Engert (GC-HBOC). GC-HBOC would like to thank the 800 
following persons for providing additional informations and samples: Prof. Dr. Norbert 801 
Arnold, Dr. Sabine Preissler-Adams, Dr. Monika Mareeva-Varon, Dr. Dieter Niederacher, 802 
Prof. Dr. Brigitte Schlegelberger, Dr. Clemens Mül. The GENICA Network: Dr. Margarete 803 
Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, 804 
Germany; [HB, Wing-Yee Lo, Christina Justenhoven], German Cancer Consortium (DKTK) 805 
and German Cancer Research Center (DKFZ) [HB], Department of Internal Medicine, 806 
Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany [YDK, 807 
Christian Baisch], Institute of Pathology, University of Bonn, Germany [Hans-Peter Fischer], 808 
Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), 809 
Heidelberg, Germany [Ute Hamann] and Institute for Prevention and Occupational Medicine 810 
of the German Social Accident Insurance, Institute of the Ruhr University Bochum  (IPA), 811 
Bochum, Germany [TB, Beate Pesch, Sylvia Rabstein, Anne Lotz]; Institute of Occupational 812 
Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany 813 
 33 
[Volker Harth]. HEBCS thanks Kirsimari Aaltonen, Tuomas Heikkinen, and Dr. Karl von 814 
Smitten and RN Irja Erkkilä for their help with the HEBCS data and samples. We thank Peter 815 
Hillemanns, Hans Christiansen and Johann H. Karstens (HMBCS), Eija Myöhänen, Helena 816 
Kemiläinen (KBCP). kConFab thanks Heather Thorne, Eveline Niedermayr, the AOCS 817 
Management Group (D Bowtell, G Chenevix-Trench, A deFazio, D Gertig, A Green, P 818 
Webb), the ACS Management Group (A Green, P Parsons, N Hayward, P Webb, D 819 
Whiteman). LAABC thanks all the study participants and the entire data collection team, 820 
especially Annie Fung and June Yashiki. We thank Gilian Peuteman, Dominiek 821 
Smeets, Thomas Van Brussel and Kathleen Corthouts (LMBC). MARIE would like to thank 822 
Alina Vrieling, Katharina Buck, Muhabbet Celik, Ursula Eilber and Sabine Behrens for their 823 
valuable contributions to data management and assessment, and Lars Beckmann, Thomas 824 
Illig, Kirsten Mittelstraß for their valuable contributions to analysis and generation of the 825 
GWAS data. MBCSG thank Bernard Peissel, Giulietta Scuvera and Daniela Zaffaroni of the 826 
Fondazione IRCCS Istituto Nazionale dei Tumori (INT); Monica Barile and Irene Feroce of 827 
the Istituto Europeo di Oncologia (IEO) and the personnel of the Cogentech Cancer Genetic 828 
Test Laboratory. We would like to Martine Tranchant (CHU de Québec Research Center), 829 
Marie-France Valois, Annie Turgeon and Lea Heguy (McGill University Health Center, 830 
Royal Victoria Hospital; McGill University) for DNA extraction, sample management and 831 
skillful technical assistance (MTLGEBCS). J.S. is Chairholder of the Canada Research Chair 832 
in Oncogenetics. We thank Phuah Sze Yee, Peter Kang, Kang In Nee, Kavitta Sivanandan, 833 
Shivaani Mariapun, Yoon Sook-Yee, Daphne Lee, Teh Yew Ching and Nur Aishah Mohd 834 
Taib for DNA Extraction and patient recruitment (MYBRCA). We thank Mervi Grip, Meeri 835 
Otsukka, Kari Mononen (OBCS), and Teresa Selander, Nayana Weerasooriya (OFBCR). 836 
ORIGO thanks E. Krol-Warmerdam, and J. Blom for patient accrual, administering 837 
questionnaires, and managing clinical information. The LUMC survival data were retrieved 838 
from the Leiden hospital-based cancer registry system (ONCDOC) with the help of Dr. J. 839 
 34 
Molenaar. We thank Mark Sherman, Stephen Chanock, Neonila Szeszenia-Dabrowska, 840 
Beata Peplonska, Witold Zatonski, Pei Chao, Michael Stagner (PBCS). SASBAC and 841 
pKARMA thank The Swedish Medical Research Counsel. We thank Petra Bos, Jannet Blom, 842 
Ellen Crepin, Anja Nieuwlaat, Annette Heemskerk, the Erasmus MC Family Cancer Clinic 843 
(RBCS), and Sue Higham, Helen Cramp, Ian Brock, Sabapathy Balasubramanian, Jenny 844 
Barrett, Mark Iles, John Taylor and Dan Connley (SBCS). We thank the SEARCH and EPIC 845 
teams, and Breakthrough Breast Cancer and the Institute of Cancer Research for support and 846 
funding of the Breakthrough Generations Study. We thank Muriel Adank for selecting the 847 
samples and Margreet Ausems, Christi van Asperen, Senno Verhoef, and Rogier van 848 
Oldenburg for providing samples from their Clinical Genetic centers (DFBBCS). The 849 
SGBCC would like to thank the participants and research coordinator Kimberley Chua. The 850 
results published here are in part based upon data generated by The Cancer Genome Atlas 851 
pilot project established by the NCI and NHGRI (dbGAP phs000178.v8.p7, accessed 15
th
 852 
November 2013). Information about TCGA and the investigators and institutions who 853 
constitute the TCGA research network can be found at http://cancergenome.nih.gov. We also 854 
thank Westra et al. for the provision of eQTL data at http://genenetwork.nl/bloodeqtlbrowser/. 855 
The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the 856 
Office of the Director of the National Institutes of Health 857 
(commonfund.nih.gov/GTEx).  Additional funds were provided by the NCI, NHGRI, NHLBI, 858 
NIDA, NIMH, and NINDS.  Donors were enrolled at Biospecimen Source Sites funded by 859 
NCI\SAIC-Frederick, Inc. (SAIC-F) subcontracts to the National Disease Research 860 
Interchange (10XS170), Roswell Park Cancer Institute (10XS171), and Science Care, Inc. 861 
(X10S172).  The Laboratory, Data Analysis, and Coordinating Center (LDACC) was funded 862 
through a contract (HHSN268201000029C) to the The Broad Institute, Inc.  Biorepository 863 
operations were funded through an SAIC-F subcontract to Van Andel Institute (10ST1035). 864 
Additional data repository and project management were provided by SAIC-F 865 
 35 
(HHSN261200800001E).  Statistical Methods development grants were made to the 866 
University of Geneva (MH090941), the University of Chicago (MH090951 & MH090937), 867 
the University of North Carolina - Chapel Hill (MH090936) and to Harvard University 868 
(MH090948).  The datasets used for the analyses described in this manuscript were obtained 869 
from the GTEx Portal on 01/16/2014. 870 
 871 
Conflict of Interest Statement. None declared 872 
 873 
References 874 
 875 
1 Stratton, M.R. and Rahman, N. (2008) The emerging landscape of breast cancer 876 
susceptibility. Nat. Genet., 40, 17-22. 877 
2 Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J., Milne, R.L., 878 
Schmidt, M.K., Chang-Claude, J., Bojesen, S.E., Bolla, M.K. et al. (2013) Large-scale 879 
genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet., 45, 353-361. 880 
3 Welter D., MacArthur J., Morales J., Burdett T., Hall P., Junkins H., Klemm A., 881 
Flicek P., Manolio T., Hindorff L. et al. (2014) The NHGRI GWAS Catalog, a curated 882 
resource of SNP-trait associations. Nucleic Acids Res., 42, D1001-D1006. 883 
4 MacPherson, G., Healey, C.S., Teare, M.D., Balasubramanian, S.P., Reed, M.W.R., 884 
Pharoah, P.D.P., Ponder, B.A.J., Meath, M., Bhattacharyya, N.P. and Cox, A. (2004) 885 
Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J. 886 
Natl. Cancer Inst., 96, 1866-1869. 887 
5 Cox, A., Dunning, A.M., Garcia-Closas, M., Balasubramanian, S., Reed, M.W.R., 888 
Pooley, K.A., Scollen, S., Baynes, C., Ponder, B.A.J., Chanock, S. et al. (2007) A common 889 
coding variant in CASP8 is associated with breast cancer risk. Nat. Genet., 39, 352-358. 890 
 36 
6 Shephard, N.D., Abo, R., Rigas, S.H., Frank, B., Lin, W.Y., Brock, I.W., Shippen, A., 891 
Balasubramanian, S.P., Reed, M.W.R., Bartram, C.R. et al. (2009) A Breast Cancer Risk 892 
Haplotype in the Caspase-8 Gene. Cancer Res., 69, 2724-2728. 893 
7 Camp, N.J., Parry, M., Knight, S., Abo, R., Elliott, G., Rigas, S.H., Balasubramanian, 894 
S.P., Reed, M.W., McBurney, H., Latif, A. et al. (2012) Fine-mapping CASP8 risk variants in 895 
breast cancer. Cancer Epidemiol. Biomarkers Prev., 21, 176-181. 896 
8 Turnbull, C., Ahmed, S., Morrison, J., Pernet, D., Renwick, A., Maranian, M., Seal, S., 897 
Ghoussaini, M., Hines, S., Healey, C.S. et al. (2010) Genome-wide association study 898 
identifies five new breast cancer susceptibility loci. Nat. Genet., 42, 504-U547. 899 
9 Hoggart, C.J., Whittaker, J.C., De Iorio, M. and Balding, D.J. (2008) Simultaneous 900 
Analysis of All SNPs in Genome-Wide and Re-Sequencing Association Studies. PLoS Genet., 901 
4, e1000130. 902 
10 Westra, H.J., Peters, M.J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J., 903 
Christiansen, M.W., Fairfax, B.P., Schramm, K., Powell, J.E. et al. (2013) Systematic 904 
identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet., 905 
45, 1238-1243. 906 
11 Hnisz, D., Abraham, B.J., Lee, T.I., Lau, A., Saint-Andr√©, V., Sigova, A.A., Hoke, 907 
H.A. and Young, R.A. (2013) Super-Enhancers in the Control of Cell Identity and Disease. 908 
Cell, 155, 934-947. 909 
12 Barrett, J.H., Iles, M.M., Harland, M., Taylor, J.C., Aitken, J.F., Andresen, P.A., 910 
Akslen, L.A., Armstrong, B.K., Avril, M.F., Azizi, E. et al. (2011) Genome-wide association 911 
study identifies three new melanoma susceptibility loci. Nat. Genet., 43, 1108-1113. 912 
13 Berndt, S.I., Skibola, C.F., Joseph, V., Camp, N.J., Nieters, A., Wang, Z., Cozen, W., 913 
Monnereau, A., Wang, S.S., Kelly, R.S. et al. (2013) Genome-wide association study 914 
identifies multiple risk loci for chronic lymphocytic leukemia. Nat. Genet., 45, 868-876. 915 
 37 
14 Howie, B.N., Donnelly, P. and Marchini, J. (2009) A Flexible and Accurate Genotype 916 
Imputation Method for the Next Generation of Genome-Wide Association Studies. PLoS 917 
Genet., 5, e1000529. 918 
15 Howie, B., Marchini, J. and Stephens, M. (2011) Genotype imputation with thousands 919 
of genomes. G3 (Bethesda, Md.), 1, 457-470. 920 
16 Benjamini, Y. and Hochberg, Y. (1995) Controlling the False Discovery Rate - a 921 
Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B-Methodol., 57, 922 
289-300. 923 
17 French, J.D., Ghoussaini, M., Edwards, S.L., Meyer, K.B., Michailidou, K., Ahmed, 924 
S., Khan, S., Maranian, M.J., O'Reilly, M., Hillman, K.M. et al. (2013) Functional Variants at 925 
the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range 926 
Enhancers. Am. J. Hum. Genet., 92, 489-503. 927 
18 Viechtbauer, W. (2010) Conducting Meta-Analyses in R with the metafor Package. J. 928 
Stat. Softw., 36, 1-48. 929 
19 Wang, K., Li, M. and Hakonarson, H. (2010) ANNOVAR: functional annotation of 930 
genetic variants from high-throughput sequencing data. Nucleic Acids Res., 38, e164. 931 
20 Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., 932 
Boehnke, M., Abecasis, G.R. and Willer, C.J. (2010) LocusZoom: regional visualization of 933 
genome-wide association scan results. Bioinformatics, 26, 2336-2337. 934 
 935 
 936 
937 
 38 
Legends to Figures 938 
Figure 1 939 
Breast cancer associations within the 1Mb region surrounding CASP8.  940 
The upper panel plots SNPs based on their chromosomal coordinates on the x axis and their p 941 
values on the –log10 scale on the y axis. Circle and diamond symbols represent typed and 942 
imputed SNPs respectively. The colours indicate the pairwise r
2
 with index SNP for iCHAV1, 943 
rs1830298 (highlighted in purple); r
2
 are calculated based on the European panel in the 1000 944 
genomes project. The ranges of iCHAVs 1-4 are indicated with coloured shading. Genes 945 
within the region are indicated in the lower panel, with arrows indicating transcript direction, 946 
dense blocks for exons and lines for introns. The plot was generated using LocusZoom (20). 947 
 948 
Figure 2 949 
Associations of the 4 index SNPs corresponding to iCHAVs 1-4, and the two previous 950 
associations, in iCOGS European subjects and GWAS data.  951 
Squares denote the per-allele OR for the minor allele based on iCOGS and nine GWAS data, 952 
with the size of the square proportional to the sample size. Diamonds represent the pooled 953 
estimates of ORs under the fixed effect model after exclusion of the 1955 samples from the 954 
iCOGS data that were also in the combined GWAS data. Index SNPs correspond to iCHAVs 955 
as follows: rs1830298; iCHAV1, rs36043647; iCHAV2, rs59278883; iCHAV3, rs7558475 956 
iCHAV4. 957 
 958 
Figure 3 959 
Study-specific OR for the minor allele of rs1830298 in iCOGS European, Asian and 960 
African-American subjects.  961 
Squares denote the individual study per-allele OR and diamonds indicate the combined effects, 962 
with the size of the symbol indicating sample size. Fixed effect models (FE model) were used 963 
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to combine the study ORs if p for the Cochran’s Q test (phet) was greater than 0.05, otherwise 964 
random effect models (RE model) were used. Pooled OR across the 3 populations is shown, 965 
with phet and I-squared for heterogeneity in parenthesis. 966 
 967 
Figure 4 968 
Associations between rs1830298 and clinical subtypes of breast cancer in iCOGS 969 
European subjects. 970 
Squares denote the individual study per-allele OR with the size of the symbol indicating 971 
sample size. Cases in each subtype group were compared to all controls. 972 
 973 
Figure 5 974 
Summary of the CASP8/ALS2CR12 locus. 975 
The locations of iCHAVs and lead SNPs are shown relative to genes. eQTL SNPs are 976 
displayed as red marks. ENCODE DNaseI hypersenitive sites derived from various mammary 977 
cell types are depicted as gray marks. H3K27ac histone modification ChIP-seq data is shown 978 
as well as predicted enhancers and target genes from Hnisz et al (11). 979 
980 
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 981 
Abbreviations 982 
BCAC: Breast Cancer Association Consortium 983 
CI: confidence interval 984 
CLL: chronic lymphocytic leukaemia 985 
COGS: Collaborative Oncology Gene- environment Study 986 
DNase: deoxyribonuclease 987 
eQTL: expression quantitative trait locus/loci 988 
ER: estrogen receptor 989 
FPKM: fragments per Kb of transcript per million mapped reads 990 
GWAS: genome-wide association studies 991 
HMEC: human mammary epithelium cells 992 
HR: hazard ratio 993 
iCHAV independent sets of correlated highly associated variants 994 
iCOGS: Collaborative Oncology Gene- environment Study genotyping array 995 
Kb: kilobase 996 
MAF: minor allele frequency 997 
Mb: megabase 998 
OR: odds ratio 999 
SNP: Single nucleotide polymorphism 1000 
TCGA: The Cancer Genome Atlas 1001 
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